Committees on Neurobiology and Molecular Medicine, Departments of Neurology and Neurobiology, Pharmacology, & Physiology, The University of Chicago, USA.
J Clin Neurol. 2005 Oct;1(2):107-20. doi: 10.3988/jcn.2005.1.2.107. Epub 2005 Oct 20.
Despite successful treatment of Parkinson's disease (PD) with a wide variety of symptomatic therapy, the disease continues to progress and drug-resistance symptoms become the predominant factors producing the disability of PD patients. Neuroprotective therapies have been tested, but clinically effective drugs have not been found yet. New insights gained from studies of genetic forms of PD point to the common pathogenic mechanisms that have been suspected in sporadic forms of the disease and may provide new approaches for the future neuroprotective therapies.
尽管通过各种对症治疗成功地治疗了帕金森病 (PD)，但该疾病仍在继续发展，并且耐药症状成为导致 PD 患者残疾的主要因素。已经测试了神经保护疗法，但尚未发现临床有效的药物。从 PD 的遗传形式研究中获得的新见解指向了在散发性疾病中已被怀疑的共同发病机制，并可能为未来的神经保护疗法提供新的方法。
